This phase II trial tests whether combining the immunotherapy drug pembrolizumab (Keytruda) with the hormone therapy fulvestrant (Faslodex) can help control advanced or metastatic breast cancer that is hormone receptor positive and HER2 negative. The study includes 47 adults and …
Phase: PHASE2 • Sponsor: Nancy Chan, MD • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC